The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
Patients over 18 years of age;
Histological diagnosis of clear cell renal cell carcinoma;
Evidence of advanced or metastatic disease;
Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
Previous neoplasms;
Previous antineoplastic treatments;
Previous steroid treatments;
Active viral infections (e.g., HCV, HIV, etc.);
Patients with metastatic clear cell renal cell carcinoma starting first-line immunotherapy
Other
Prospective
Not listed
Torquetenovirus in numbers of copies/ml
To descriptively evaluate the trend of torquetenovirus TTV viral load measured in number of copies/milliliter using a quantitative method, i.e. a REAL TIME PCR, during treatment with immunotherapy in patients with metastatic clear cell renal cell carcinoma starting a first-line treatment.
Microbiome assessment
Microbiome will be described in terms of the type of microbial species present.
Click on the lead sponsor to view all of their trials.
